Dublin, April 23, 2026 (GLOBE NEWSWIRE) — The “Cancer Biomarkers Market – Types, Applications and Technologies” report has been added to ResearchAndMarkets.com’s offering.
The global market for Cancer Biomarkers is estimated at US$27.6 billion in 2025 and is projected to reach US$58 billion by 2032, with a CAGR of 11.2% during the forecast period 2025-2032.
Biomarkers help classify cancer, predict clinical outcomes, and guide treatment decisions, while also supporting risk assessment, monitoring how patients respond to therapy, and detecting recurrence at earlier stages. Ideal biomarkers are reliable, cost-effective, detectable early, and reflective of tumor burden, though validation is challenging due to tumor heterogeneity.
Detection relies on technologies such as NGS, PCR/ddPCR, mass spectrometry, immunoassays, cytogenetics, and imaging, supported by bioinformatics. Liquid biopsy methods, using ctDNA, CTCs, and exosomes, are expanding non-invasive testing options. Overall, biomarkers are central to personalized oncology, strengthening early detection, refining treatment decisions, and improving patient management.
The global cancer biomarkers market is expanding rapidly, driven by the escalating global cancer burden, the urgent need for earlier and more accurate diagnosis, and breakthrough advancements in omics technologies such as genomics, proteomics, and transcriptomics. With millions of new cancer cases reported annually, driven by aging populations and unhealthy lifestyle shifts, healthcare systems are prioritizing earlier detection and more accurate molecular profiling. Demand for personalized oncology is accelerating, supported by the increasing use of next-generation sequencing (NGS), real-time PCR, and liquid biopsy platforms capable of analyzing circulating tumor DNA and CTCs.
Precision medicine initiatives such as the NHS Genomic Medicine Service and the U.S. NCI’s Early Detection Research Network are expanding biomarker discovery and clinical validation. AI-enabled analytics are enhancing diagnostic accuracy by processing high-dimensional omics and imaging datasets, lowering turnaround times by up to 40% through automated workflows.
The market is further strengthened by the rising adoption of non-invasive diagnostic tools, the commercialization of multiplex biomarker panels, and growth in companion diagnostics linked to targeted therapies, such as HER2-directed breast cancer treatments or KRAS-guided colorectal therapy decisions.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 326 |
| Forecast Period | 2025 – 2032 |
| Estimated Market Value (USD) in 2025 | $27.6 Billion |
| Forecasted Market Value (USD) by 2032 | $58 Billion |
| Compound Annual Growth Rate | 11.2% |
| Regions Covered | Global |
Key Market Players
- Abbott Laboratories
- Agilent Technologies, Inc
- Becton, Dickinson and Company (BD)
- bioMerieux SA
- Bio-Rad Laboratories, Inc.
- Exact Sciences Corporation
- Guardant Health, Inc.
- Hologic, Inc.
- Illumina, Inc.
- Merck KGaA
- Myriad Genetics Inc.
- Qiagen N.V.
- Quest Diagnostics
- Roche Holding AG
- Siemens Healthineers
- Thermo Fisher Scientific Inc.
Key Metrics
- Historical Period: 2022-2024
- Base Year: 2025
- Forecast Period: 2025-2032
- Units: Value market in US$
- Companies Mentioned: 15+
Cancer Biomarkers Market by Geographic Region
- North America (The United States, Canada, and Mexico)
- Europe (Germany, France, the United Kingdom, Italy, Spain, and Rest of Europe)
- Asia-Pacific (Japan, China, India, South Korea, and Rest of Asia-Pacific)
- South America (Brazil, Argentina, and Rest of South America)
- Rest of World
Cancer Biomarkers Market by Type
- Genetic Biomarkers
- Epigenetic Biomarkers
- Metabolic Biomarkers
- Proteomic Biomarkers
- Other Types (Including Circulating Tumor Cells (CTCs), Immune Biomarkers, Glycoprotein Biomarkers, and others)
Cancer Biomarkers Market by Cancer Type
- By Cancer Type
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Blood Cancers (Leukemia, Lymphoma)
- Liver Cancer
- Other Cancer Types (Including Melanoma, Ovarian, Cervical, Kidney, Bladder, and other cancers)
Cancer Biomarkers Market by Application
- Diagnostics
- Personalized Medicine
- Drug Discovery and Development
- Other Applications (Including Prognostics, Risk Assessment, Research & Development, Screening, Monitoring, and others)
Cancer Biomarkers Market by Technology
- Omics Technologies
- Imaging Technologies
- Immunoassay
- Cytogenetics
- Other Technologies (Including Bioinformatics, Next-Generation Sequencing (NGS), PCR, Mass Spectrometry, and others)
For more information about this report visit https://www.researchandmarkets.com/r/jfm7od
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
